Business Context and Reporting Period
This Form 8-K is filed by PharmAthene, Inc. (not Altimmune, Inc.) on August 8, 2014, reporting a significant legal development regarding its litigation with SIGA Technologies, Inc. The filing details a Memorandum Opinion and Order issued by the Delaware Court of Chancery on August 8, 2014, concerning the valuation of lost profits for the smallpox antiviral Tecovirimat (ST-246).
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity for the reporting period. The document focuses exclusively on the legal determination of damages.
- Damages Award Status: The Court found PharmAthene entitled to lump sum expectation damages for lost profits, plus pre-judgment and post-judgment interest, and varying percentages of attorneys' and expert witness fees.
- Valuation Model Adjustments: The Court ordered a recalculation of the damages model with specific constraints:
- Timeframe: Reduced from 2006-2017 to 2006-2014.
- Sales Timing: First sales shifted from 2008 to 2010.
- Sales Volume: 2010 sales capped at 2,980,649 courses (SNS and DoD only; no worldwide sales).
- Pricing: $100 per course in 2010, increasing 3% annually through 2014.
- Cost of Goods Sold (COGS): Fixed at 14% of revenues starting in 2010.
- R&D Expenses: Fixed at $2 million per year from 2010 to 2014.
- Discount Rate: 23.1% annual discount rate with an 84% probability of success factor.
- Attorneys' Fees: Awarded 40% of fees incurred through post-trial argument and one-third of fees incurred during remand proceedings.
Material Changes Versus Prior Period
The filing represents a material change in the legal remedy available to the Company compared to prior proceedings:
- Remedy Type: The Delaware Supreme Court previously reversed an equitable payment stream remedy. The Chancery Court now mandates a lump sum expectation damages award based on lost profits.
- Claim Dismissal: The Court denied and dismissed with prejudice claims for specific performance of a license agreement or an equitable payment stream, limiting the remedy to contractual damages.
- Expected Value: Management expects the final calculated award to be significantly lower than the amount initially presented by the Company's expert using the original model.
Guidance, Outlook, Risks, and Contingencies
Outlook and Guidance: The Company cannot provide a definitive estimate of the award amount as substantial calculations remain to be completed by its valuation expert. The final amount is subject to further proceedings and approval by the Chancery Court.
Risks and Contingencies:
- Appeal Risk: The decision is subject to appeal to the Delaware Supreme Court, where SIGA may seek reversal or remand.
- Collection Risk: There is no assurance the Company will receive payments; SIGA may lack sufficient cash to satisfy the award.
- Calculation Uncertainty: The final amount depends on complex calculations involving variables not fully detailed in the filing.
- Disagreement: Disagreement between the parties regarding the final amount is expected before Chancery Court approval.
Important Facts for Investor Verification
- Confirm the identity of the registrant as PharmAthene, Inc., noting the discrepancy with the requested company name (Altimmune, Inc.).
- Verify that no specific dollar amount for the damages award is currently available; only the methodology for calculation has been established.
- Monitor SIGA Technologies' financial health to assess the likelihood of collecting any potential judgment.
- Track the status of the appeal process to the Delaware Supreme Court, which could alter or reverse the damages award.
- Review future filings for the final calculated damages amount once the Company's expert completes the revised model.